Hbw Advisory Services 13F: Cuts Merck (MRK) Stake by $1.2M

Hbw Advisory Services scaled back its investment in Merck & Co., Inc. (NYSE:MRK), trimming its holdings by 31.7% during the period. The latest Form 13F filing filed with the Securities and Exchange Commission shows the firm disposed of 8,583 shares. That left Hbw Advisory Services holding 18,454 shares of the healthcare company, with a total reported value of $2,681,621. Because 13F filings look backward at portfolio snapshots, this report reflects holdings as of the close of the period and may not represent the firm's current positioning today.

What Changed in Hbw Advisory Services's Merck & Co., Inc. Position

Before the adjustment, Hbw Advisory Services held 27,037 shares of Merck. Dropping 8,583 shares brought the position down to 18,454 shares, marking a 31.7% decrease for the fund. The remaining block of stock carried a reported market value of about $2.7 million at the time of the filing. Institutional portfolio shifts like this happen for many reasons, including routine rebalancing or locking in gains after price moves.

Other Institutional Activity in Merck & Co., Inc.

Other major investment managers also tweaked their positions in Merck during recent reporting cycles. Blackrock Inc. grew its holdings by 1,174,293 shares, ending with 226,999,837 shares worth about $33.3 billion after a 0.5% increase. Vanguard Capital Management LLC lifted its stake by 338,069 shares, growing its holdings 0.2% to 161,323,174 shares valued at roughly $23.7 billion. State Street Corporation added 1,085,879 shares for a 0.9% increase, wrapping up the period with 120,413,256 shares worth about $17.7 billion. Wellington Management Group, LLP raised its stake by 1,930,891 shares, or 2.3%, to hold 86,249,283 shares valued at approximately $12.6 billion. Finally, Vanguard Portfolio Management LLC boosted its position by 437,460 shares, representing a 0.6% increase to 67,738,969 shares worth about $9.9 billion.

Merck & Co., Inc. Stock Up 1.1%

Shares of Merck trade near $146.78, sitting well above their 200-day moving average of $120.70. The stock has traded between a 52-week low of $77.58 and a 52-week high of $156.92. The company carries a massive market value of $368.8 billion. Its trailing P/E ratio sits at 119.6, while the forward P/E drops to a more moderate 15.7 based on near-term earnings expectations.

Recent Earnings

Merck posted $65.6 billion in revenue over the trailing period, reflecting a 5.1% growth rate. The company generated earnings of $1.25 per share, alongside a net margin of 4.8% and a return on equity of 7.0%. Investors are looking ahead to the next corporate earnings update scheduled for October 29, 2026.

Dividend

Merck rewards shareholders with an annual dividend rate of $3.40 per share, giving the stock a dividend yield of 2.31%. The company's dividend payout ratio stands at 2.69.

Insider Buying and Selling at Merck & Co., Inc.

Company insiders have also transacted in company stock recently. On June 30, 2026, insider Karsanbhai Surendralal Lanca bought 127 shares at an average price of $128.50, totaling $16,319.50. On the same day, Christine Seidman purchased 63 shares at $128.50 for a total of $8,095.50, and Mary Ellen Coe picked up 234 shares at $128.50 worth $30,069.00. Later, on August 13, 2026, officer Chirfi Guindo sold 10,000 shares at a price of $135.00, generating $1,350,000.00. None of these transactions were reported as part of a Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Wall Street analysts continue to review Merck's outlook with fresh ratings and price targets. On October 12, 2026, Citigroup maintained a Neutral rating on the stock while lifting its price target from $125.00 to $145.00. On the same day, RBC Capital kept a Sector Perform rating and adjusted its target from $150.00 down to $145.00. Cantor Fitzgerald maintained a Neutral rating on October 8, 2026, raising its target from $120.00 to $145.00. Morgan Stanley kept an Overweight rating on October 7, 2026, nudging its target from $179.00 to $177.00. JP Morgan maintained an Overweight rating on October 5, 2026, pushing its target up from $150.00 to $165.00. Across the broader analyst community, Merck holds a consensus recommendation key of buy, backed by a mean target price of $152.96 across 26 analyst opinions.

About Merck & Co., Inc.

Headquartered in Rahway, New Jersey, Merck & Co. operates as a major global healthcare company focusing on human health pharmaceuticals and vaccines. Its product lineup features widely known treatments and preventative medicines across oncology, infectious diseases, and immunology, anchored by blockbusters like Keytruda and Gardasil. Institutional position shifts, such as the reduction by Hbw Advisory Services, offer a window into how smaller wealth managers adjust their portfolios alongside massive institutional funds.

Bottom Line

As investors digest recent portfolio adjustments, market participants will watch for the upcoming earnings release on October 29, 2026, to gauge ongoing revenue trends. Form 13F filings provide a historical look at institutional ownership but do not reflect live trading activity. Readers should review subsequent regulatory filings for any newer changes in position.